|
|
ChemoCellomics™
2cureX’s core technology, ChemoCellomics™, integrates synthesis
of “high-value” compound libraries with high throughput screening
(HTS) in primary cells from patients.
This unique drug discovery platform allows 2cureX to identify drug candidates
that are selected based on their efficacy against cancer cells whereas
healthy cells from the same patients remain unaffected. Tumours and
associated metastases develop over years and show considerable heterogeneity
within and between patients.
The recent identification of cancer stem cells stresses the importance
of accepting and exploiting the biological complexity at the outset
of drug discovery
2cureX is convinced that the overall success and effectiveness of drug
discovery can be greatly improved by conducting the initial drug hit
and lead selection directly in primary cells from patients.
|
